Cargando…

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.

Detalles Bibliográficos
Autores principales:	Sotirios, Papageorgiou, Bouchla, Anthi, Gkontopoulos, Konstantinos, Thomopoulos, Thomas, Loukari, Constantinos, Apostolopoulou, Christina, Vryttia, Pinelopi, Zormpa, Artemis, Tsakatikas, Sergios, Pappa, Vasiliki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429966/ http://dx.doi.org/10.1097/01.HS9.0000973820.33926.c2

Ejemplares similares

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience
por: Bouchla, Anthi, et al.
Publicado: (2019)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION
por: Gore, L., et al.
Publicado: (2022)

PB1787: GADD45A IS OVER-EXPRESSED IN THE BONE MARROW OF PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA REFRACTORY TO INDUCTION CHEMOTHERAPY
por: Bouchla, A., et al.
Publicado: (2022)

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?
por: Bouchla, Anthi, et al.
Publicado: (2023)

Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone
por: Papageorgiou, Sotirios, et al.
Publicado: (2020)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
por: Fokoloros, Christos, et al.
Publicado: (2022)

PB2085: UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.
por: Naylor, G. U., et al.
Publicado: (2022)

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis
por: Papageorgiou, Sotirios G., et al.
Publicado: (2017)

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report
por: Bouchla, Anthi, et al.
Publicado: (2018)

Red Blood Cell Abnormalities as the Mirror of SARS-CoV-2 Disease Severity: A Pilot Study
por: Bouchla, Anthi, et al.
Publicado: (2022)

PB2036: RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA
por: VA, A., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2347: THE ROLE OF UPFRONT LENALIDOMIDE MAINTENANCE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS RESPONDING TO FIRST-LINE MTX TREATMENT
por: Zhang, Yan, et al.
Publicado: (2023)

PB1843: ACUTE MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME: EXPERIENCE OF SFAX HEMATOLOGY DEPARTMENT
por: Siala, N., et al.
Publicado: (2022)

Production mechanism of the X(1740) meson
por: Alde, D, et al.
Publicado: (1991)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

Scottish philosophy and British physics, 1740-1870
por: Olson, Richard S
Publicado: (2015)

The “Throat Distemper” of 1735-1740: Part II
por: Caulfield, Ernest
Publicado: (1939)

PB1750: PHILADELPHIA CHROMOSOME POSITIVE ALL EGYPTIAN PATIENTS: CLINICAL PROFILE & OUTCOME. A SINGLE CENTER EXPERIENCE.
por: Shaaban, Yasmine, et al.
Publicado: (2023)

PB1724: NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
por: LI, Yanming, et al.
Publicado: (2023)

Erdheim–Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report
por: Papageorgiou, Sotirios G, et al.
Publicado: (2020)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

Chemistry, medicine, and the legitimization of English spas, 1740-1840.
por: Hamlin, C.
Publicado: (1990)

Comunas en el nuevo mundo, 1740-1971 /
por: Ungers, Liselotte
Publicado: (1978)

Pain and Surgery in England, circa 1620–circa 1740
por: Walker, Katherine A.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i82p30op3t54pnd7qqaipbg2cl